Challenges in the analytical method development and validation for an unstable active pharmaceutical ingredient.
A sensitive high-performance liquid chromatography (HPLC) impurity profile method for the antibiotic ertapenem is developed and subsequently validated. The method utilizes an Inertsil phenyl column at ambient temperature, gradient elution with aqueous sodium phosphate buffer at pH 8, and acetonitrile as the mobile phase. The linearity, method precision, method ruggedness, limit of quantitation, and limit of detection of the impurity profile HPLC method are found to be satisfactory. The method is determined to be specific, as judged by resolving ertapenem from in-process impurities in crude samples and degradation products that arise from solid state thermal and light stress, acid, base, and oxidative stressed solutions. In addition, evidence is obtained by photodiode array detection studies that no degradate or impurity having a different UV spectrum coeluted with the major component in stressed or unstressed samples. The challenges during the development and validation of the method are discussed. The difficulties of analyzing an unstable active pharmaceutical ingredient (API) are addressed. Several major impurities/degradates of the API have very different UV response factors from the API. These impurities/degradates are synthesized or prepared by controlled degradation and the relative response factors are determined.
Sajonz
Peter
P
Merck Research Laboratories, Merck & Co., Inc., P.O. Box 2000, RY801-A101, Rahway, NJ 07065, USA.
Wu
Yan
Y
Natishan
Theresa K
TK
McGachy
Neil T
NT
Detora
David
D
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004355:Drug Stability; D000077727:Ertapenem; D004364:Pharmaceutical Preparations / Q000032:analysis; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D047090:beta-Lactams / Q000032:analysis* / Q000592:standards
D004364:Pharmaceutical Preparations; D047090:beta-Lactams; D000077727:Ertapenem